Hepatitis C

Hepatitis C News

  • NASH: The Next Untapped Pharma Market Gives Investors Many Options Large drugmakers with piles of cash are on the hunt for promising medicines being developed by small companies to treat non-alcoholic steatohepatitis (NASH), a progressive fatty liver disease poised to become the leading cause of liver transplants by 2020.
  • 8-week Sofosbuvir-velpatasvir-voxilaprevir Less Effective for HCV For patients with chronic hepatitis C virus (HCV) infection, eight weeks of combined sofosbuvir-velpatasvir-voxilaprevir may not be as effective as 12 weeks of only sofosbuvir-velpatasvir, results from two phase 3 open-label trials suggest.
 

Hepatitis C Perspective